By-health Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000Y84
CNY
11.88
-0.22 (-1.82%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

17.33 M

Shareholding (Jun 2017)

FII

0.02%

Held by 1 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of 1.23% and Operating profit at 34.47% over the last 5 years

 
2

The company has declared Negative results for the last 6 consecutive quarters

3

With ROE of 4.51%, it has a fair valuation with a 1.18 Price to Book Value

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 13,185 Million (Large Cap)

stock-summary
P/E

26.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

4.64%

stock-summary
Debt Equity

-0.43

stock-summary
Return on Equity

4.51%

stock-summary
Price to Book

1.18

Revenue and Profits:
Net Sales:
1,721 Million
(Quarterly Results - Jun 2025)
Net Profit:
297 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.42%
0%
0.42%
6 Months
0.68%
0%
0.68%
1 Year
-7.19%
0%
-7.19%
2 Years
-34.83%
0%
-34.83%
3 Years
-42.77%
0%
-42.77%
4 Years
-49.81%
0%
-49.81%
5 Years
-54.08%
0%
-54.08%

By-health Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
1.23%
EBIT Growth (5y)
34.47%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.66
Tax Ratio
29.36%
Dividend Payout Ratio
92.88%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
21.48%
ROE (avg)
14.00%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
1.18
EV to EBIT
13.05
EV to EBITDA
9.10
EV to Capital Employed
1.31
EV to Sales
1.46
PEG Ratio
NA
Dividend Yield
4.64%
ROCE (Latest)
10.06%
ROE (Latest)
4.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2017stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -11.62% vs -20.93% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 84.18% vs -68.79% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,720.50",
          "val2": "1,946.70",
          "chgp": "-11.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "420.60",
          "val2": "187.30",
          "chgp": "124.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.90",
          "val2": "1.80",
          "chgp": "116.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "26.00",
          "val2": "31.80",
          "chgp": "-18.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "296.90",
          "val2": "161.20",
          "chgp": "84.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "201.20%",
          "val2": "63.70%",
          "chgp": "13.75%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.17% vs 19.64% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -63.58% vs 26.04% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,782.90",
          "val2": "9,313.70",
          "chgp": "-27.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "998.80",
          "val2": "2,098.40",
          "chgp": "-52.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "13.80",
          "val2": "4.70",
          "chgp": "193.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "28.00",
          "val2": "50.60",
          "chgp": "-44.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "647.90",
          "val2": "1,778.80",
          "chgp": "-63.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "109.60%",
          "val2": "199.10%",
          "chgp": "-8.95%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1,720.50
1,946.70
-11.62%
Operating Profit (PBDIT) excl Other Income
420.60
187.30
124.56%
Interest
3.90
1.80
116.67%
Exceptional Items
26.00
31.80
-18.24%
Consolidate Net Profit
296.90
161.20
84.18%
Operating Profit Margin (Excl OI)
201.20%
63.70%
13.75%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -11.62% vs -20.93% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 84.18% vs -68.79% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
6,782.90
9,313.70
-27.17%
Operating Profit (PBDIT) excl Other Income
998.80
2,098.40
-52.40%
Interest
13.80
4.70
193.62%
Exceptional Items
28.00
50.60
-44.66%
Consolidate Net Profit
647.90
1,778.80
-63.58%
Operating Profit Margin (Excl OI)
109.60%
199.10%
-8.95%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -27.17% vs 19.64% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -63.58% vs 26.04% in Dec 2023

stock-summaryCompany CV
About By-health Co., Ltd. stock-summary
stock-summary
By-health Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available